BTK阻害剤TL-895との薬物相互作用の責任
Jack C Stromatt1, Eman A Ahmed1, Thomas Drabison1
1The Ohio State University, Columbus, Ohio, United States.
Cancer research communications
|August 22, 2025
まとめ
二重のBTK/ BMX阻害剤であるTL-895は,BMXの強力な阻害を示しています. OATP1B1とCYP3A4の基質ですが,薬物相互作用を引き起こす可能性は低いため,組み合わせ療法ではより安全です.
科学分野:
- 薬理学について
- 薬の代謝と薬動力学
- 腫瘍学
背景:
- 新薬の薬物相互作用 (DDI) に関する初期段階のデータは限られている.
- 標的外関わりとトランスポーター/酵素の相互作用を理解することは,薬の安全性と有効性にとって極めて重要です.
研究 の 目的:
- TL-895のキナーゼ相互作用プロフィールを特徴づける.
- OATP1B1とCYP3A4の基質としてのTL- 895の薬物相互作用 (DDI) を評価する.
主な方法:
- キナーゼ阻害測定法 (IC50) とBRET測定法が酵素阻害を決定するために使用された.
- OATP1B1とCYP3A4によるDDIの可能性を評価するために,in vitroおよびin vivoモデルを使用した.
- 酵素媒介の相互作用を評価するために,CYP3Aゼロのマウスで薬理学的な研究が行われました.
主要な成果:
- TL-895はブルトンチロシンキナーゼ (BTK) とBmxの両方を強力に抑制し,Bmxに対してより強い効能を有する (IC50: 0. 53 nM).
- TL-895は肝臓のトランスポーターOATP1B1と酵素CYP3A4の基質として特定されています.
- TL-895はOATP1B1基質の 血濃度を増やさなかった このトランスポーター経由で DDIを起こす可能性は低い
- CYP3A4の抑制により,CYP3AゼロのマウスではTL-895の血濃度が上昇し,CYP3A4の代謝における役割が確認された.
結論:
- TL-895は,定義されたキナーゼ相互作用プロファイルを持つ二重BTK/ BMX阻害剤です.
- OATP1B1とCYP3A4はTL- 895の体内の分解に大きく貢献する.
- TL-895は臨床的に有意なOATP1B1媒介のDDIの起因者である可能性は低いため,多剤療法におけるその潜在的な使用を支持する.
関連する概念動画
Factors Affecting Protein-Drug Binding: Drug Interactions
273
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
273
Combined Effects of Drugs: Antagonism
9.2K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.2K
Protein-Drug Binding: Mechanism and Kinetics
931
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
931
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Drug Distribution: Tissue Binding
3.2K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
3.2K


